Patents by Inventor Mehran Moghaddam

Mehran Moghaddam has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230158035
    Abstract: Provided herein are Aminopurine Compounds having the following structures: wherein R1, R2, and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound, and methods for treating or preventing a cancer, for example, melanoma.
    Type: Application
    Filed: January 11, 2023
    Publication date: May 25, 2023
    Inventors: Matthew Alexander, Sogole Bahmanyar, John Frederick Boylan, Joshua Hansen, Dehua Huang, Robert Hubbard, Brandon Jeffy, Jim Leisten, Mehran Moghaddam, Raj K. Raheja, Heather Raymon, Kimberly Schwarz, Marianne Sloss, Eduardo Torres, Tam Minh Tran, Shuichan Xu, Jingjing Zhao
  • Patent number: 11590139
    Abstract: Provided herein are Aminopurine Compounds having the following structures: wherein R1, R2, and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound, and methods for treating or preventing a cancer, for example, melanoma.
    Type: Grant
    Filed: January 12, 2021
    Date of Patent: February 28, 2023
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Matthew Alexander, Sogole Bahmanyar, John Frederick Boylan, Joshua Hansen, Dehua Huang, Robert Hubbard, Brandon Jeffy, Jim Leisten, Mehran Moghaddam, Raj K. Raheja, Heather Raymon, Kimberly Schwarz, Marianne Sloss, Eduardo Torres, Tam Minh Tran, Shuichan Xu, JingJing Zhao
  • Publication number: 20210128565
    Abstract: Provided herein are Aminopurine Compounds having the following structures: wherein R1, R2, and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound, and methods for treating or preventing a cancer, for example, melanoma.
    Type: Application
    Filed: January 12, 2021
    Publication date: May 6, 2021
    Inventors: Matthew Alexander, Sogole Bahmanyar, John Frederick Boylan, Joshua Hansen, Dehua Huang, Robert Hubbard, Brandon Jeffy, Jim Leisten, Mehran Moghaddam, Raj K. Raheja, Heather Raymon, Kimberly Schwarz, Marianne Sloss, Eduardo Torres, Tam Minh Tran, Shuichan Xu, JingJing Zhao
  • Patent number: 10940152
    Abstract: Provided herein are Aminopurine Compounds having the following structures: wherein R1, R2, and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound, and methods for treating or preventing a cancer, for example, melanoma.
    Type: Grant
    Filed: April 13, 2020
    Date of Patent: March 9, 2021
    Assignee: SIGNAL PHARMACEUTICALS, LLC
    Inventors: Matthew Alexander, Sogole Bahmanyar, John Frederick Boylan, Joshua Hansen, Dehua Huang, Robert Hubbard, Brandon Jeffy, Jim Leisten, Mehran Moghaddam, Raj K. Raheja, Heather Raymon, Kimberly Schwarz, Marianne Sloss, Eduardo Torres, Tam Minh Tran, Shuichan Xu, JingJing Zhao
  • Publication number: 20200237768
    Abstract: Provided herein are Aminopurine Compounds having the following structures: wherein R1, R2, and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound, and methods for treating or preventing a cancer, for example, melanoma.
    Type: Application
    Filed: April 13, 2020
    Publication date: July 30, 2020
    Inventors: Matthew Alexander, Sogole Bahmanyar, John Frederick Boylan, Joshua Hansen, Dehua Huang, Robert Hubbard, Brandon Jeffy, Jim Leisten, Mehran Moghaddam, Raj K. Raheja, Heather Raymon, Kimberly Schwarz, Marianne Sloss, Eduardo Torres, Tam Minh Tran, Shuichan Xu, JingJing Zhao
  • Patent number: 10646493
    Abstract: Provided herein are Aminopurine Compounds having the following structures: wherein R1, R2, and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound, and methods for treating or preventing a cancer, for example, melanoma.
    Type: Grant
    Filed: July 17, 2019
    Date of Patent: May 12, 2020
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Matthew Alexander, Sogole Bahmanyar, John Frederick Boylan, Joshua Hansen, Dehua Huang, Robert Hubbard, Brandon Jeffy, Jim Leisten, Mehran Moghaddam, Raj K. Raheja, Heather Raymon, Kimberly Schwarz, Marianne Sloss, Eduardo Torres, Tam Minh Tran, Shuichan Xu, JingJing Zhao
  • Patent number: 9737541
    Abstract: Provided herein are Aminopurine Compounds having the following structures: wherein R1, R2, and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound, and methods for treating or preventing a cancer, for example, melanoma.
    Type: Grant
    Filed: October 27, 2016
    Date of Patent: August 22, 2017
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Matthew Alexander, Sogole Bahmanyar, Joshua Hansen, Dehua Huang, Robert Hubbard, Brandon Jeffy, Jim Leisten, Mehran Moghaddam, Raj K. Raheja, Heather Raymon, Kimberly Schwarz, Marianne Sloss, Eduardo Torres, Tam Minh Tran, Shuichan Xu, JingJing Zhao, John Frederick Boylan
  • Publication number: 20170042902
    Abstract: Provided herein are Aminopurine Compounds having the following structures: wherein R1, R2, and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound, and methods for treating or preventing a cancer, for example, melanoma.
    Type: Application
    Filed: October 27, 2016
    Publication date: February 16, 2017
    Inventors: Matthew Alexander, Sogole Bahmanyar, Joshua Hansen, Dehua Huang, Robert Hubbard, Brandon Jeffy, Jim Leisten, Mehran Moghaddam, Raj K. Raheja, Heather Raymon, Kimberly Schwarz, Marianne Sloss, Eduardo Torres, Tam Minh Tran, Shuichan Xu, JingJing Zhao, John Frederick Boylan
  • Patent number: 9512124
    Abstract: Provided herein are Aminopurine Compounds having the following structures: wherein R1, R2, and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound, and methods for treating or preventing a cancer, for example, melanoma.
    Type: Grant
    Filed: October 5, 2015
    Date of Patent: December 6, 2016
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Matthew Alexander, Sogole Bahmanyar, Joshua Hansen, Dehua Huang, Robert Hubbard, Brandon Jeffy, Jim Leisten, Mehran Moghaddam, Raj K. Raheja, Heather Raymon, Kimberly Schwarz, Marianne Sloss, Eduardo Torres, Tam Minh Tran, Shuichan Xu, JingJing Zhao, John Frederick Boylan
  • Publication number: 20160096841
    Abstract: Provided herein are Aminopurine Compounds having the following structures: wherein R1, R2, and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound, and methods for treating or preventing a cancer, for example, melanoma.
    Type: Application
    Filed: October 5, 2015
    Publication date: April 7, 2016
    Inventors: Matthew Alexander, Sogole Bahmanyar, Joshua Hansen, Dehua Huang, Robert Hubbard, Brandon Jeffy, Jim Leisten, Mehran Moghaddam, Raj K. Raheja, Heather Raymon, Kimberly Schwarz, Marianne Sloss, Eduardo Torres, Tam Minh Tran, Shuichan Xu, JingJing Zhao, John Frederick Boylan
  • Patent number: 7647047
    Abstract: Consumer configurable mobile communications solution enabling policy-enforcement services allowing authorized users to define, manage and enforce restrictions for voice, data, and mobile Web services of a secondary mobile device.
    Type: Grant
    Filed: December 21, 2007
    Date of Patent: January 12, 2010
    Assignee: Ventraq Corporation
    Inventors: Mehran Moghaddam, Guido Jonjie S. Sena, Jr., Carlos Bernardino Eleazer Perez
  • Patent number: 7516219
    Abstract: Consumer configurable mobile communications solution enabling web filtering based on policy-enforcement services allowing authorized users to define, manage and enforce restrictions for mobile web data and services of a secondary mobile device.
    Type: Grant
    Filed: January 22, 2008
    Date of Patent: April 7, 2009
    Assignee: Ventraq Corporation
    Inventors: Mehran Moghaddam, Jonjie Sena, Carlos Bernardino Eleazar Perez
  • Publication number: 20080114862
    Abstract: Consumer configurable mobile communications solution enabling web filtering based on policy-enforcement services allowing authorized users to define, manage and enforce restrictions for mobile web data and services of a secondary mobile device.
    Type: Application
    Filed: January 22, 2008
    Publication date: May 15, 2008
    Applicant: Ace*Comm Corporation
    Inventors: Mehran Moghaddam, Jonjie Sena, Carlos Bernardino Perez
  • Publication number: 20080096539
    Abstract: Consumer configurable mobile communications solution enabling policy-enforcement services allowing authorized users to define, manage and enforce restrictions for voice, data, and mobile Web services of a secondary mobile device.
    Type: Application
    Filed: December 21, 2007
    Publication date: April 24, 2008
    Applicant: Ace*Comm Corporation
    Inventors: Mehran MOGHADDAM, Guido Jonjie Sena, Carlos Bernardino Perez
  • Publication number: 20080065746
    Abstract: Consumer configurable mobile communications solution enabling web filtering based on policy-enforcement services allowing authorized users to define, manage and enforce restrictions for mobile web data and services of a secondary mobile device.
    Type: Application
    Filed: June 4, 2007
    Publication date: March 13, 2008
    Applicant: ACE*COMM CORPORATION
    Inventors: Mehran Moghaddam, Jonjie Sena, Carlos Bernardino Eleazar PEREZ
  • Publication number: 20070117782
    Abstract: The invention provides compounds that inhibit epoxide hydrolase in therapeutic applications for treating hypertension. A preferred class of compounds for practicing the invention have the structure shown by Formula 1 wherein Z is oxygen or sulfur, W is carbon phosphorous or sulfur, X and Y is each independently nitrogen, oxygen, or sulfur, and X can further be carbon, at least one of R1-R4 is hydrogen, R2 is hydrogen when X is nitrogen but is not present when X is sulfur or oxygen, R4 is hydrogen when Y is nitrogen but is not present when Y is sulfur or oxygen, R1 and R3 is each independently C1-C20 substituted or unsubstituted alkyl, cycloalkyl, aryl, acyl, or heterocyclic.
    Type: Application
    Filed: December 1, 2006
    Publication date: May 24, 2007
    Applicant: The Regents of the University of California
    Inventors: Bruce Hammock, Jiang Zheng, Christophe Morisseau, Kazuhiko Motoba, Mehran Moghaddam, Babak Borhan, David Grant, Jessica Greene, Marlene Sisemore, James Sanborn
  • Publication number: 20070073874
    Abstract: Consumer configurable mobile communications solution enabling policy-enforcement services allowing authorized users to define, manage and enforce restrictions for voice, data, and mobile Web services of a secondary mobile device.
    Type: Application
    Filed: September 7, 2006
    Publication date: March 29, 2007
    Inventors: Mehran Moghaddam, Jonjie Sena, Carlos Perez